ADBICA, also known as ADB-PICA, surfaced as a designer drug within synthetic cannabis blends in Japan back in 2013. Notably, before its inclusion as a component of synthetic cannabis blends, ADBICA had remained absent from scientific literature. This compound shares a distinctive feature with SDB-001 and STS-135, namely the presence of a carboxamide group at the 3-indole position. Regarding the stereochemistry of the tert-butyl side-chain in the product, it still needs to be solved. However, in a significant array of indazole derivatives closely related to ADBICA, as disclosed in Pfizer patent WO 2009/106980, the pharmacological activity is exclusively attributed to the (S) enantiomers. ADBICA stands out as a potent agonist, affecting the CB1 and CB2 receptors with remarkable potency, displaying EC50 values of 0.69 nM and 1.8 nM, respectively.
|CAS Number||racemate: 1445583-48-1|
|PubChem CID||racemate: 72710773|
|UNII||racemate: Q71G788A6HS isomer: P0248QCZ04|
|CompTox Dashboard (EPA)||racemate: DTXSID801009996|
|Chemical and physical data|
|Molar mass||343.471 g·mol−1|
As of October 2015 ADBICA is a controlled substance in China.
1. What is ADBICA?
ADBICA, also known as ADB-PICA, is a designer drug that was identified in synthetic cannabis blends in Japan in 2013.
2. How was ADBICA discovered?
ADBICA was discovered as a component of synthetic cannabis blends in Japan in 2013. It had not been previously reported in scientific literature before its inclusion in these blends.
3. What makes ADBICA unique in terms of its chemical structure?
ADBICA features a distinctive carboxamide group at the 3-indole position, a structural feature it shares with compounds like SDB-001 and STS-135.
4. What is the stereochemistry of ADBICA’s tert-butyl side-chain?
The stereochemistry of ADBICA’s tert-butyl side chain remains unresolved. However, it’s worth noting that in a series of structurally similar indazole derivatives disclosed in a Pfizer patent (WO 2009/106980), the pharmacological activity is attributed exclusively to the (S) enantiomers.
5. What is the pharmacological effect of ADBICA on cannabinoid receptors?
ADBICA is a potent agonist of both the CB1 receptor and the CB2 receptor. It displays remarkable potency with an EC50 value of 0.69 nM for CB1 and 1.8 nM for CB2, making it a potent activator of these receptors.
6. Is ADBICA legal and safe to use?
The legal status of ADBICA varies by region and country. Its safety is a subject of concern, as the use of synthetic cannabinoids can have unpredictable and potentially harmful effects. Users should be aware of and adhere to local regulations.
7. Can ADBICA be used for medical purposes?
ADBICA is primarily recognized as a research chemical and not for medical use. Its potential therapeutic applications still need to be established.
8. What are the potential risks associated with ADBICA use?
Using synthetic cannabinoids like ADBICA can pose various risks, including potential health hazards, unknown long-term effects, and possible legal consequences.
9. Where can I find more information about ADBICA?
To gain a more comprehensive understanding of ADBICA, consider referring to scientific literature, research studies, and relevant authorities. Staying informed about the latest developments is crucial.
10. How can I seek help for substance abuse or addiction related to synthetic cannabinoids?
If you or someone you know is struggling with substance abuse or addiction, numerous organizations and resources are available to provide assistance and support. Seek help from addiction treatment centres or support groups for guidance.
- In 2013, Uchiyama N, Matsuda S, Kawamura M, Kikura-Hanajiri R, and Goda Y made significant findings in their research, uncovering “Two new-type cannabimimetic quinolinyl carboxylates, QUPIC and QUCHIC, two new cannabimimetic carboxamide derivatives, ADB-FUBINACA and ADBICA,” alongside the detection of “five synthetic cannabinoids.” Their discoveries also included the identification of a thiophene derivative, α-PVT, and an opioid receptor agonist, AH-7921, all within illegal products. This research was documented in “Forensic Toxicology,” Volume 31, Issue 2, covering pages 223–240. To delve further into their findings, refer to doi:10.1007/s11419-013-0182-9. Additionally, this publication can be found on S2CID 1279637.
- WO 2009/106980, credited to Buchler IP and et al., titled “Indazole Derivatives,” is assigned to Pfizer, Inc., and presents valuable insights into indazole derivatives.
- In September 2015, Banister SD, Moir M, Stuart J, Kevin RC, Wood KE, Longworth M, and their colleagues conducted research focusing on the “Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs.” Their study encompassed various compounds, including AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA. Their findings were published in “ACS Chemical Neuroscience,” Volume 6, Issue 9, with the article spanning pages 1546–1559. You can explore further details through doi:10.1021/acschemneuro.5b00112, and the PMID for this publication is 26134475.
- The “关于印发《非药用类麻醉药品和精神药品列管办法》的通知” (in Chinese) was issued by the China Food and Drug Administration on September 27, 2015. It pertains to the administration’s notification regarding the “Measures for the Supervision and Control of Non-Medicinal Narcotic Drugs and Psychotropic Drugs.” This notification is a significant regulatory development in the control of such substances.